NCT02673697

Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement

Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement A Controlled Randomized Trial in the Surgical Treatment of Aortic Valve Disease

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 914 (actual)
• Sponsor: Corcym S.r.l · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Prospective, randomized, stratified non blinded multi-center, international, post market trial assessed in a non-inferiority study. The trial has a flexible sample size that will be determined adaptively. The trial will enroll up to 1234 subjects, but accrual may stop earlier at approximately 900 or 1050 subjects These subjects will be enrolled at approximately 60 worldwide investigational sites where the device is commercially available The primary objective of this trial is to test the safety and efficacy of Perceval versus standard sutured stented bioprosthetic aortic valves among the intended trial population.

Detailed description

PERSIST-AVR is designed to collect data on sutureless valve (Perceval sutureless aortic heart valve), a new type of biological aortic valve, comparing data with standard biological aortic valve, considered the gold standard for aortic valve replacement. This prospective, randomized international multicenter study is planned to demonstrate, as primary endpoint, the non inferiority of Major Adverse Cardiac and Cerebrovascular (MACCE) events at one year while showing superiority in resource consumptions at hospital discharge in patients treated with Perceval valve when compared to standard aortic valve replacement. The study is planned to cover the lack of prospective, randomized comparison data between sutureless valve and standard aortic biological sutured valve. The trial has a flexible sample size that will be determined adaptively. The trial will enroll up to 1234 subjects, but accrual may stop earlier at approximately 900 or 1050 subjects. These subjects will be enrolled at approximately 60 worldwide investigational sites where the device is commercially available. The primary endpoint will be reached at 1 year FU and, consequently, the planned primary analysis will be performed 12 months following the end of accrual. The be part of the trial, investigational sites should have demonstrated experience with the implantation of the Perceval and able to implement the requirements of the study protocol.. All subjects with severe symptomatic aortic stenosis or steno-insufficiency who are candidates for surgical replacement of their native aortic valve according to established guidelines in current medical practice and as specified in the Perceval valve Instruction for Use (IFU) are the intended population for inclusion in this randomized trial.

Conditions

• Aortic Valve Disease
• Aortic Stenosis

Interventions

Type	Name	Description
DEVICE	Perceval valve	Sutureless Aortic Biological Valve
DEVICE	other stented biological valve	Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)

Timeline

• Start date: 2016-03-22
• Primary completion: 2020-01-17
• Completion: 2020-07-31
• First posted: 2016-02-04
• Last updated: 2024-03-06
• Results posted: 2022-07-27

Locations

47 sites across 12 countries: United States, Austria, Belgium, Canada, Chile, France, Germany, Israel, Italy, Netherlands, Spain, United Kingdom